Healthcare -
Biotechnology - NASDAQ - US
$ 1.2
-4 %
$ 3.68 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart SONN
FINANCIALS
Balance Sheet
Sonnet BioTherapeutics Holdings, Inc.
| Current Assets | 2.12 M |
| Cash & Short-Term Investments | 149 K |
| Receivables | 0 |
| Other Current Assets | 1.97 M |
| Non-Current Assets | 653 K |
| Long-Term Investments | 0 |
| PP&E | 144 K |
| Other Non-Current Assets | 509 K |
| Current Liabilities | 3.21 M |
| Accounts Payable | 2.18 M |
| Short-Term Debt | 84.3 K |
| Other Current Liabilities | 942 K |
| Non-Current Liabilities | 46.6 K |
| Long-Term Debt | 46.6 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Sonnet BioTherapeutics Holdings, Inc.
| Revenue | 18.6 K |
| Cost Of Revenue | 0 |
| Gross Profit | 18.6 K |
| Operating Expenses | 11.9 M |
| Operating Income | -11.8 M |
| Other Expenses | -4.41 M |
| Net Income | -7.44 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sonnet BioTherapeutics Holdings, Inc.
| Net Income | -7.44 M |
| Depreciation & Amortization | 83.1 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 231 K |
| Change in Working Capital | -1.9 M |
| Others | -1.53 M |
| Free Cash Flow | -8.61 M |
Wall Street Analysts Price Targets
Sonnet BioTherapeutics Holdings, Inc.
SONN has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SONN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sonnet BioTherapeutics Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
globenewswire.com
- 2 weeks ago
Sonnet Announces Release of Corporate Update Video
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here.
globenewswire.com
- 2 weeks ago
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends to launch a CEO search.
globenewswire.com
- 2 weeks ago
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS)
globenewswire.com
- 3 weeks ago
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) thus making IL-18 BPR more effective in vitro
globenewswire.com
- 1 month ago
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here
globenewswire.com
- 1 month ago
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® ) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.
globenewswire.com
- 1 month ago
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
globenewswire.com
- 2 months ago
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA.
globenewswire.com
- 2 months ago
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.
globenewswire.com
- 2 months ago
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)
globenewswire.com
- 2 months ago
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
globenewswire.com
- 2 months ago
8. Profile
Summary
Sonnet BioTherapeutics Holdings, Inc. SONN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.68 M
Dividend Yield
0.00%
Description
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Contact
100 Overlook Center, Princeton, NJ, 08540
https://www.sonnetbio.com
IPO
Date
Oct. 31, 2006
Employees
13
Officers
Mr. Donald J. Griffith CPA, CPA
Chief Financial Officer, Financial Controller & Director
Dr. John K. Cini Ph.D.
Chief Scientific Officer & Co-Founder